24. R. Hilfiker, F. Blatter, and M.V. Raumer, "Relevance of Solid-State Properties for Pharmaceutical Products," in Polymorphism in the Pharmaceutical Industry, R. Hilfiker, Ed. (Wiley–VCH, Weinheim, Germany, 2006), pp. 1–19.
25. S. Balbach and C. Korn, "Pharmaceutical Evaluation of Early Development Candidates—the 100-mg Approach," Int. J. Pharm.
275 (1–2), 1–12 (2004).
26. G. Davies, "Changing the Salt, Changing the Drug," Pharm. J.
266 (7138), 322–323 (2001).
27. J.D. Higgins and W.L. Rocco, "Pharma Preformulation: A Stop Along the Drug Development Highway," Today's Chemist at Work
12 (7), 22–26 (2003).
28. A.T.M. Serajuddin et al., "Preformulation Study of a Poorly Water Soluble Drug α-pentyl-3-(2-quinolinylmethoxy) benzenemethanol:
Selection of the Base for Dosage Form Design," J. Pharm. Sci.
75 (5), 492–496 (1986).
29. R.J. Bastin, M.J. Bowker, and B.J. Slater, "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical
Entities," Org. Proc. Res. Dev.
4 (5), 427–435 (2000).
30. "Orinase Diagnostic-Product Information,"
http://www.pfizer.com/pfizer/download/uspi_orinase.pdf, accessed Jan. 21, 2006.
31. R.M. Everett et al., "Nephrotoxicity of Pravadoline Maleate (WIN 48098-6) in Dogs: Evidence of Maleic Acid-Induced Acute
Tubular Necrosis," Fundam. Appl. Toxicol.
21 (1), 59–65 (1993).
32. D. J. Snodin, "Residues of Genotoxic Alkyl Mesylates in Mesylate Salt Drug Substances: Real or Imaginary Problems?,"
Regul.Toxicol. Pharmacol.
45 (1), 79–90 (2006).
33. A. Allerman, "New Drug Watch,"
http://www.pec.ha.osd.mil/Updates/0307web/Aug-Sep_03_Update_Page_5.htm, accessed Dec. 15, 2006.
34. W.Q. Tong and G. Whitesell, "In situ Salt Screening—A Useful Technique for Discovery Support and Preformulation Studies,"
Pharm. Dev. Technol.
3 (2), 215–223 (1998).
35. C.R. Gardner et al., "Application of High Throughput Technologies to Drug Substance and Drug Product Development," Comput. Chem. Eng.
28 (6–7), 943–953 (2004).
36. A.W. Newman and G.P. Stahly, "Form Selection of Pharmaceutical Compounds," in Handbook of Pharmaceutical Analysis, vol. 117, L. Ohannesian and A.J. Streeter, Eds. (Marcel Dekker, New York, 2002), pp. 1–58.
37. G.L. Engel et al., "Salt Form Selection and Characterization of LY333531 Mesylate Monohydrate," Int. J. Pharm.
198 (2), 239–247 (2000).
|
